Filter Jobs
45
Available Jobs
Find your perfect opportunity
Specialist, Logistics Program
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
System Administrator, Global LIMS
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Manager, Patient Advocacy & Engagement
Remote
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Associate Director, Revenue Accounting
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Technician, Quality Assurance, 2nd shift
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Head, Site Onboarding & Market Enablement
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Manager, Global Quality Management System (QMS)
Remote
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Specialist, Payroll
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Director, Scientific Communications
Remote
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Technician, Quality Control, 3rd Shift
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Technician, Quality Control Environmental Monitoring, 1st Shift
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Senior Scientist, Quality Control, Microbiology
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Material Handler, 3rd Shift
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Cell Therapy Case Management Lead
Remote
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Scientist, Quality Control
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Director, Medical Information
Remote
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Cell Therapy Case Manager
Remote
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Analyst, Commercial Data and Business Intelligence
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Specialist, Production Project Support
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Technician, Quality Control, 2nd Shift
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Technician, Quality Control, 1st Shift
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee
Technician, Quality Assurance, 1st shift
Summary:
More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotecEmployment Type: Regular, Full-Time Employee